KR101505347B1 - 신경퇴행성 증상의 치료를 위한 인간 신경 세포의 이식 - Google Patents

신경퇴행성 증상의 치료를 위한 인간 신경 세포의 이식 Download PDF

Info

Publication number
KR101505347B1
KR101505347B1 KR1020137020263A KR20137020263A KR101505347B1 KR 101505347 B1 KR101505347 B1 KR 101505347B1 KR 1020137020263 A KR1020137020263 A KR 1020137020263A KR 20137020263 A KR20137020263 A KR 20137020263A KR 101505347 B1 KR101505347 B1 KR 101505347B1
Authority
KR
South Korea
Prior art keywords
cells
neurons
spinal cord
nscs
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020137020263A
Other languages
English (en)
Korean (ko)
Other versions
KR20130092634A (ko
Inventor
마틴 마살라
칼 케이. 조
토마스 쥐. 하젤
오사무 가끼노하마
바실리스 콜리앗소스
준 얀
폴 제이. 레이어
마가렛 제이. 벨라도
Original Assignee
뉴럴스템, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴럴스템, 인크. filed Critical 뉴럴스템, 인크.
Publication of KR20130092634A publication Critical patent/KR20130092634A/ko
Application granted granted Critical
Publication of KR101505347B1 publication Critical patent/KR101505347B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/148—Transforming growth factor alpha [TGF-a]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
KR1020137020263A 2004-11-17 2005-11-17 신경퇴행성 증상의 치료를 위한 인간 신경 세포의 이식 Expired - Lifetime KR101505347B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62922004P 2004-11-17 2004-11-17
US60/629,220 2004-11-17
PCT/US2005/041631 WO2006055685A2 (en) 2004-11-17 2005-11-17 Transplantation of human neural cells for treatment of neurodegenerative conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077012097A Division KR101429284B1 (ko) 2004-11-17 2005-11-17 신경퇴행성 증상의 치료를 위한 인간 신경 세포의 이식

Publications (2)

Publication Number Publication Date
KR20130092634A KR20130092634A (ko) 2013-08-20
KR101505347B1 true KR101505347B1 (ko) 2015-03-23

Family

ID=36407743

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137020263A Expired - Lifetime KR101505347B1 (ko) 2004-11-17 2005-11-17 신경퇴행성 증상의 치료를 위한 인간 신경 세포의 이식
KR1020077012097A Expired - Fee Related KR101429284B1 (ko) 2004-11-17 2005-11-17 신경퇴행성 증상의 치료를 위한 인간 신경 세포의 이식

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077012097A Expired - Fee Related KR101429284B1 (ko) 2004-11-17 2005-11-17 신경퇴행성 증상의 치료를 위한 인간 신경 세포의 이식

Country Status (13)

Country Link
US (6) US7691629B2 (enExample)
EP (2) EP1814979B1 (enExample)
JP (3) JP5424559B2 (enExample)
KR (2) KR101505347B1 (enExample)
CN (2) CN101084303A (enExample)
ES (1) ES2537004T3 (enExample)
HK (1) HK1202238A1 (enExample)
IL (2) IL183092A (enExample)
IN (1) IN2014CN03629A (enExample)
NO (1) NO340914B1 (enExample)
PH (1) PH12015501195B1 (enExample)
RU (2) RU2434636C2 (enExample)
WO (1) WO2006055685A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838292B1 (en) * 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
US8491883B2 (en) * 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
WO2006055685A2 (en) 2004-11-17 2006-05-26 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
US20060216276A1 (en) 2005-03-07 2006-09-28 Mari Dezawa Use of materials for treatment of central nervous system lesions
GB0822246D0 (en) 2008-12-05 2009-01-14 Reneuron Ltd Composition
CA2747757C (en) * 2008-12-19 2020-11-03 Ethicon, Incorporated Umbilical cord tissue derived cells for treating neuropathic pain and spasticity
CA2747794C (en) 2008-12-19 2018-10-30 Advanced Technologies And Regenerative Medicine, Llc Treatment of lung and pulmonary diseases and disorders
GB0902034D0 (en) * 2009-02-06 2009-03-11 Reneuron Ltd Method
US10386360B2 (en) 2009-03-13 2019-08-20 University Of Central Florida Research Foundation, Inc. Bio-microelectromechanical system transducer and associated methods
CN102498204B (zh) 2009-03-26 2015-02-04 德普伊新特斯产品有限责任公司 人脐带组织细胞作为用于阿尔茨海默病的疗法
US9163216B1 (en) 2009-04-23 2015-10-20 University Of Central Florida Research Foundation, Inc. Method for culturing skeletal muscle for tissue engineering
US8815584B1 (en) 2009-04-23 2014-08-26 University Of Central Florida Research Foundation, Inc. Method of co-culturing mammalian muscle cells and motoneurons
US8828721B1 (en) 2009-05-28 2014-09-09 University Of Central Florida Research Foundation, Inc. Method of myelinating isolated motoneurons
US9404140B1 (en) 2009-11-03 2016-08-02 The University Of Central Florida Research Foundation, Inc. Patterned cardiomyocyte culture on microelectrode array
US9489474B2 (en) 2010-02-05 2016-11-08 University Of Central Florida Research Foundation, Inc. Model and methods for identifying points of action in electrically active cells
CA2798777C (en) 2010-04-23 2016-09-06 University Of Central Florida Research Foundation, Inc. Formation of neuromuscular junctions in a defined system
RU2013108868A (ru) * 2010-07-28 2014-09-10 Ньюралстем, Инк. Способы лечения и/или реверсии нейродегенеративных заболеваний и/или расстройств
US9498554B2 (en) 2012-07-24 2016-11-22 S.C. Johnson & Son, Inc. Dispensing device
US20150219622A1 (en) 2012-08-17 2015-08-06 University Of Central Florida Research Foundation, Inc. Methods, systems and compositions for functional in vitro cellular models of mammalian systems
US10357517B1 (en) 2012-10-01 2019-07-23 University Of South Florida Methods of treating epilepsy using neural stem cells that express nanog, SSEA-4, OCT-4, MIR-34B, MIR-34C and MIR-592
RU2515475C1 (ru) * 2012-11-15 2014-05-10 Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК Способ стимуляции образования децидуальной оболочки эндометрия в эксперименте
US10694747B2 (en) 2012-11-21 2020-06-30 S. C. Johnson & Son, Inc. Dispenser comprising only one single hinge
WO2014120952A1 (en) 2013-01-30 2014-08-07 University Of Central Florida Research Foundation, Inc. Devices and systems for mimicking heart function
WO2014138003A1 (en) * 2013-03-04 2014-09-12 Neuralstem, Inc. Compositions comprising an immunosuppressive drug and/or neural stem cells and methods of using same for the treatment of neurodegenerative diseases and/or disorders
EP3498824A1 (en) 2013-04-26 2019-06-19 Memorial Sloan-Kettering Cancer Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
CN104278008B (zh) 2013-07-12 2020-08-21 北京宏冠再生医学科技有限公司 一种通过小分子化合物处理来制备多潜能干细胞的方法、试剂盒和用途
US10947500B2 (en) * 2014-06-27 2021-03-16 Angiocrine Bioscience, Inc. Neural cells expressing adenovirus E4ORF1, and methods of making and using the same
KR101675123B1 (ko) * 2014-06-27 2016-11-14 연세대학교 산학협력단 Psa-ncam-양성 신경전구세포를 유효성분으로 포함하는 허혈성 질환 또는 신경염증 질환 치료용 조성물
US10935541B2 (en) 2014-08-07 2021-03-02 University Of Central Florida Research Foundation, Inc. Devices and methods comprising neuromuscular junctions
EP3209306B1 (en) 2014-10-20 2024-04-24 Neuralstem, Inc. Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
US10286009B2 (en) * 2015-05-16 2019-05-14 Asterias Biotherapeutics, Inc. Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury
US11028369B2 (en) 2015-08-13 2021-06-08 Beihao Stem Cell And Regenerative Medicine Research Institute Co., Ltd. Induced extended pluripotent stem cells, method of making and using
CN108934168B (zh) 2015-11-30 2022-05-03 北昊干细胞与再生医学研究院有限公司 用于将非多能细胞重编程为多能干细胞的改进方法
US11007228B2 (en) * 2016-02-05 2021-05-18 Kyungpook National University Industry-Academic Cooperation Foundation Pharmaceutical composition containing stem cell in which vascular endothelial growth factor is overexpressed as effective ingredient for preventing or treating neurodegenerative disease
US11920155B2 (en) 2016-03-30 2024-03-05 Asterias Biotherapeutics, Inc. Oligodendrocyte progenitor cell compositions
FR3058892B1 (fr) * 2016-11-23 2021-04-09 Univ Bordeaux Unite de tissu neural et utilisation d'une telle unite pour l'implantation dans le systeme nerveux d'un mammifere
CN106619722A (zh) * 2016-12-05 2017-05-10 上海安集协康生物技术股份有限公司 一种治疗脑部损伤类疾病的神经干细胞注射液
JP6500051B2 (ja) * 2017-03-17 2019-04-10 哲丸 村田 組織処理方法
EP3630948A4 (en) 2017-05-31 2020-12-30 Beihao Stem Cell and Regenerative Medicine Research Institute Co., Ltd. METHOD OF CHEMICALLY INDUCED CELL LINE REPROGRAMMING
US12365872B2 (en) 2018-09-19 2025-07-22 Lineage Cell Therapeutics, Inc. Methods for differentiating pluripotent stem cells in dynamic suspension culture
US11603518B2 (en) 2019-01-23 2023-03-14 Asterias Biotherapeutics, Inc. Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells
CN111494422B (zh) * 2019-01-29 2022-04-29 中国科学院遗传与发育生物学研究所 治疗脊髓损伤的产品及其应用
JP7015605B2 (ja) 2019-12-27 2022-02-03 株式会社Rainbow 頭蓋内に安全に細胞を投与するための総合システム
CN115166260B (zh) * 2022-07-11 2023-06-13 东南大学 血浆脑细胞来源外泌体中维生素d结合蛋白在诊断抑郁症中的应用
CN118064356A (zh) 2022-11-22 2024-05-24 浙江霍德生物工程有限公司 前脑神经前体细胞在治疗与前脑神经细胞的死亡和/或功能不全相关的疾病中的应用
WO2025097051A1 (en) 2023-11-03 2025-05-08 Axent Biosciences Inc. Thermoreversible polymers with improved stability and methods and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233838A3 (en) 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
US4753635A (en) * 1986-05-23 1988-06-28 Jacqueline Sagen Inducing analgesia by implantation of cells releasing neuroactive substances
NZ226750A (en) * 1987-10-29 1990-09-26 Amrad Corp Ltd Immortalisation of neural precursor cells by introducing a retrovirus vector containing a myc-oncogene
AU623922B2 (en) * 1988-08-04 1992-05-28 Amrad Operations Pty. Limited In vitro propagation of embryonic stem cells
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US4980174A (en) * 1988-12-23 1990-12-25 Jacqueline Sagen Method for alleviating depression
WO1991002003A1 (en) 1989-08-04 1991-02-21 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
US5411883A (en) * 1989-12-26 1995-05-02 Somatix Therapy Corporation Proliferated neuron progenitor cell product and process
WO1991009936A1 (en) 1989-12-26 1991-07-11 Hana Biologics, Inc. Proliferated neuron progenitor cell product and process
US5196315A (en) 1990-05-01 1993-03-23 The Johns Hopkins University Human neuronal cell line
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US6071889A (en) * 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US7361505B1 (en) * 1991-07-08 2008-04-22 Neurospheres Holdings Ltd. Multipotent neural stem cell compositions
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
JP4416837B2 (ja) 1991-07-08 2010-02-17 ニューロスフィアーズ ホウルディングス リミテッド 試験管内で増殖し得る新規な成長因子応答性の前駆細胞
US6294346B1 (en) * 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US6399369B1 (en) * 1991-07-08 2002-06-04 Neurospheres Holdings Ltd. Multipotent neural stem cell cDNA libraries
US6497872B1 (en) * 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
US5175103A (en) * 1991-10-21 1992-12-29 Trustees Of University Of Pennsylvania Preparation of pure cultures of post-mitotic human neurons
CA2122058C (en) 1991-11-22 2001-07-31 Peter Gluckman Tgf-beta to improve neural outcome
US5589376A (en) * 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
AU678988B2 (en) * 1992-07-27 1997-06-19 California Institute Of Technology Mammalian multipotent neural stem cells
US5693482A (en) * 1992-07-27 1997-12-02 California Institute Of Technology Neural chest stem cell assay
US5849553A (en) * 1992-07-27 1998-12-15 California Institute Of Technology Mammalian multipotent neural stem cells
AU4995193A (en) 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
WO1994004675A2 (en) 1992-08-19 1994-03-03 Richard Kroczek Dna sequence encoding a novel member of the steroid and thyroid hormone receptor family
ATE234353T1 (de) 1992-10-28 2003-03-15 Neurospheres Holdings Ltd Biologische faktoren und neuronale stammzellen
CN1141058A (zh) 1993-11-09 1997-01-22 纽罗斯菲里斯控股有限公司 中枢神经系统干细胞的原位修饰和处理
DK0783693T3 (da) 1994-09-23 2002-01-14 Neurospheres Holdings Ltd In vitro-modeller for CNS-funktion og -dysfunktion
KR970707272A (ko) 1994-11-14 1997-12-01 스코트 디. 코르맥 신경 간세포 증식 조절 방법(regulation of neural stem cell proliferation)
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5735505A (en) * 1995-04-03 1998-04-07 Data Connections, Inc. Cable pulley device and method
US5753505A (en) 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
US5770414A (en) * 1996-02-20 1998-06-23 The Regents Of The University Of California Regulatable retrovirus system for genetic modification of cells
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
JP3467154B2 (ja) * 1996-10-14 2003-11-17 パロマ工業株式会社 吸収式空調機
AU7258098A (en) 1997-04-24 1998-11-13 California Institute Of Technology Methods for differentiating neural stem cells
CA2294737A1 (en) 1997-07-04 1999-01-14 University Of Utah Research Foundation Neuron-restricted precursor cells
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US5932473A (en) * 1997-09-30 1999-08-03 Becton Dickinson And Company Preparation of a cell culture substrate coated with poly-D-lysine
US5958767A (en) * 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
EP1115841B1 (en) * 1998-09-22 2016-05-18 Neuralstem, Inc. Stable neural stem cell lines
US6284539B1 (en) * 1998-10-09 2001-09-04 Neuralstem Biopharmaceuticals, Ltd. Method for generating dopaminergic cells derived from neural precursors
US6531464B1 (en) * 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
DE60217090T2 (de) * 2001-04-23 2007-07-12 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
WO2003000852A2 (en) 2001-06-22 2003-01-03 The University Of Texas System Method of producing region-specific neurons from human neuronal stem cells
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2003046141A2 (en) * 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
WO2004072264A2 (en) * 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Fate determination by hes 1 in hematopoietic stem-progenitor cells and uses thereof
WO2006055685A2 (en) 2004-11-17 2006-05-26 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
WO2008002250A1 (en) 2006-06-30 2008-01-03 Elena Kozlova Improved stem cells for transplantation and methods for production thereof
RU2013108868A (ru) * 2010-07-28 2014-09-10 Ньюралстем, Инк. Способы лечения и/или реверсии нейродегенеративных заболеваний и/или расстройств

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny

Also Published As

Publication number Publication date
CN101084303A (zh) 2007-12-05
US20100239541A1 (en) 2010-09-23
JP5424559B2 (ja) 2014-02-26
IL204356A (en) 2011-09-27
JP5805551B2 (ja) 2015-11-04
RU2007122507A (ru) 2008-12-27
RU2434636C2 (ru) 2011-11-27
EP2913393B8 (en) 2020-02-26
JP2015062735A (ja) 2015-04-09
WO2006055685A2 (en) 2006-05-26
US9220730B2 (en) 2015-12-29
US8460651B2 (en) 2013-06-11
KR20130092634A (ko) 2013-08-20
US20100055075A1 (en) 2010-03-04
EP2913393A1 (en) 2015-09-02
US20160228471A1 (en) 2016-08-11
US10286010B2 (en) 2019-05-14
US20130251686A1 (en) 2013-09-26
US8236299B2 (en) 2012-08-07
RU2011131830A (ru) 2013-02-10
US20060141622A1 (en) 2006-06-29
EP1814979A4 (en) 2008-09-03
US20170333484A1 (en) 2017-11-23
US7691629B2 (en) 2010-04-06
CN104042629A (zh) 2014-09-17
HK1202238A1 (en) 2015-09-25
IL183092A (en) 2011-11-30
JP2012095667A (ja) 2012-05-24
EP1814979A2 (en) 2007-08-08
IL183092A0 (en) 2007-09-20
JP2008520687A (ja) 2008-06-19
ES2537004T3 (es) 2015-06-01
KR20070109979A (ko) 2007-11-15
NO340914B1 (no) 2017-07-10
KR101429284B1 (ko) 2014-08-11
PH12015501195A1 (en) 2015-12-07
EP2913393B1 (en) 2020-01-08
NO20073078L (no) 2007-08-16
PH12015501195B1 (en) 2015-12-07
WO2006055685A3 (en) 2007-03-15
JP5981526B2 (ja) 2016-08-31
EP1814979B1 (en) 2015-04-08
US9744194B2 (en) 2017-08-29
IN2014CN03629A (enExample) 2015-09-04

Similar Documents

Publication Publication Date Title
KR101505347B1 (ko) 신경퇴행성 증상의 치료를 위한 인간 신경 세포의 이식
EP2598154B1 (en) Methods for treating and/or reversing neurodegenerative diseases and/or disorders
ES2776356T3 (es) Trasplante de células neurales humanas para el tratamiento de afecciones neurodegenerativas
HK1111731A (en) Transplantation of human neural cells for treatment of neurodegenerative conditions
MXPA97003493A (en) In vitro induction of dopaminergi cells

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20130730

Application number text: 1020077012097

Filing date: 20070529

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130829

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131031

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20141226

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150317

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150317

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180307

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180307

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20190311

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20200309

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20210312

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20220304

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20240305

Start annual number: 10

End annual number: 10